

C-Abl Inhibition; A Novel Therapeutic Target for Parkinson's Disease

By: Abushouk, AI (Abushouk, Abdelrahman Ibrahim)^[1,2]; Negida, A (Negida, Ahmed)^[1,3]; Elshenawy, RA (Elshenawy, Rasha Abdelsalam)^[1,4]; Zein, H (Zein, Hossam)^[1,3]; Hammad, AM (Hammad, Ali M.)^[1,5]; Menshaw, A (Menshaw, Ahmed)^[1,6]; Mohamed, WMY (Mohamed, Wael M. Y.)^[7,8]

[View ResearcherID and ORCID](#)

CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS

Volume: 17 **Issue:** 1 **Pages:** 14-21

DOI: 10.2174/1871527316666170602101538

Published: 2018

Document Type: Review

[View Journal Impact](#)

Abstract

Parkinson's disease (PD) is the most prevalent movement disorder in the world. The major pathological hallmarks of PD are death of dopaminergic neurons and the formation of Lewy bodies. At the moment, there is no cure for PD; current treatments are symptomatic. Investigators are searching for neuroprotective agents and disease modifying strategies to slow the progress of neurodegeneration. However, due to lack of data about the main pathological sequence of PD, many drug targets failed to provide neuroprotective effects in human trials. Recent evidence suggests the involvement of C-Abelson (c-Abl) tyrosine kinase enzyme in the pathogenesis of PD. Through parkin inactivation, alpha synuclein aggregation, and impaired autophagy of toxic elements. Experimental studies showed that (1) c-Abl activation is involved in neurodegeneration and (2) c-Abl inhibition shows neuroprotective effects and prevents dopaminergic neuronal death. Current evidence from experimental studies and the first in-human trial shows that c-Abl inhibition holds the promise for neuroprotection against PD and therefore, justifies the movement towards larger clinical trials. In this review article, we discussed the role of c-Abl in PD pathogenesis and the findings of preclinical experiments and the first in-human trial. In addition, based on lessons from the last decade and current preclinical evidence, we provide recommendations for future research in this area.

Keywords

Author Keywords: Alzheimer's disease; c-Abelson; nilotinib; Parkinson's disease; tyrosine kinase inhibitors; neurological diseases

KeyWords Plus: TYROSINE KINASE INHIBITOR; ALPHA-SYNUCLEIN; OXIDATIVE STRESS; PKC-DELTA; CLINICAL PHARMACOKINETICS; PROTECTIVE FUNCTION; AMYLOID CLEARANCE; S-NITROSYLATION; NEURONAL LOSS; LEWY BODIES

Author Information

Reprint Address: Negida, A (reprint author)

+ Zagazig Univ, Fac Med, Zagazig 44519, El Shrakia, Egypt.

Addresses:

[1] Med Res Grp Egypt, Zagazig, El Sharkia, Egypt

+ [2] Ain Shams Univ, Fac Med, Cairo, Egypt

+ [3] Zagazig Univ, Fac Med, Zagazig, Elsharkia, Egypt

Citation Network

In Web of Science Core Collection

0

Times Cited

 [Create Citation Alert](#)

84

Cited References

[View Related Records](#)

Use in Web of Science

Web of Science Usage Count

1

Last 180 Days

1

Since 2013

[Learn more](#)

This record is from:

Web of Science Core Collection
- Science Citation Index Expanded

Suggest a correction

If you would like to improve the quality of the data in this record, please [suggest a correction](#).

- [+](#) [4] Tanta Univ Hosp, Tanta, Elgharbia, Egypt
- [+](#) [5] Cairo Univ, Fac Med, Cairo, Egypt
- [+](#) [6] Al Azhar Univ, Fac Med, Cairo, Egypt
- [+](#) [7] Menoufia Univ, Fac Med, Menoufia, Egypt
- [+](#) [8] Int Islamic Univ Malaysia, Fac Med, Basic Med Sci Dept, Kuantan, Malaysia

E-mail Addresses: ahmed01251@medicine.zu.edu.eg

Publisher

BENTHAM SCIENCE PUBL, PO BOX 294, BUSUM, 1400 AG, NETHERLANDS

Journal Information

Impact Factor: [Journal Citation Reports](#)

Categories / Classification

Research Areas: Neurosciences & Neurology; Pharmacology & Pharmacy

Web of Science Categories: Neurosciences; Pharmacology & Pharmacy

[See more data fields](#)

◀ 1 of 1 ▶

Cited References: 84

Showing 30 of 84 [View All in Cited References page](#)

(from Web of Science Core Collection)

1. **Psychiatric disorders among Egyptian pesticide applicators and formulators** **Times Cited: 51**
 By: Amr, MM; Halim, ZS; Moussa, SS
 ENVIRONMENTAL RESEARCH Volume: 73 Issue: 1-2 Pages: 193-199 Published: 1997
2. **Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with lewy bodies** **Times Cited: 1,018**
 By: Baba, M; Nakajo, S; Tu, PH; et al.
 AMERICAN JOURNAL OF PATHOLOGY Volume: 152 Issue: 4 Pages: 879-884 Published: APR 1998
3. **Activation of tyrosine kinase c-Abl contributes to alpha-synuclein-induced neurodegeneration** **Times Cited: 11**
 By: Brahmachari, Saurav; Ge, Preston; Lee, Su Hyun; et al.
 JOURNAL OF CLINICAL INVESTIGATION Volume: 126 Issue: 8 Pages: 2970-2988 Published: AUG 1 2016
4. **Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia** **Times Cited: 5**
 By: Breccia, Massimo; Colafigli, Gioia; Molica, Matteo; et al.
 EXPERT OPINION ON DRUG SAFETY Volume: 15 Issue: 4 Pages: 525-533 Published: APR 2 2016
5. **The role of comorbidities in chronic myeloid leukemia** **Times Cited: 4**
 By: Breccia, Massimo; Alimena, Giuliana
 LEUKEMIA RESEARCH Volume: 37 Issue: 7 Pages: 729-730 Published: JUL 2013
6. **Linked Clinical Trials - The Development of New Clinical Learning Studies in Parkinson's Disease Using Screening of Multiple Prospective New Treatments** **Times Cited: 11**
 By: Brundin, Patrik; Barker, Roger A.; Conn, P. Jeffrey; et al.
 JOURNAL OF PARKINSONS DISEASE Volume: 3 Issue: 3 Pages: 231-239 Published: 2013